CeloNova BioSciences Release: First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform New Color-Coded Embolic with Polyzene(R)-F Coating Enhances Procedural Safety, Efficiency during Treatment of Hypervasculari
Published: Jan 02, 2009
NEWNAN, Ga., Dec. 31 /PRNewswire/ -- Against the backdrop of a flagging economy, bailouts, and bleak predictions, there is a biotechnology firm in suburban Atlanta with a future as bright as New Year's Eve fireworks. Only days after receiving FDA approval to market the Embozene(TM) Color-Advanced Microspheres embolization platform for the treatment of hypervascularized tumors (tumors with a large number of blood vessels in many locations) and arteriovenous malformations (defects in the circulatory system), CeloNova BioSciences today announced that the product has been successfully used to treat several patients at two Atlanta area hospitals: Emory-Adventist Hospital in Smyrna and WellStar Windy Hill Hospital in Marietta.
(Photo: http://www.newscom.com/cgi-bin/prnh/20081231/CLW031-a )
(Photo: http://www.newscom.com/cgi-bin/prnh/20081231/CLW031-b )
(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )
Dr. John Lipman, who performed the procedures at both hospitals, said, "I was really impressed with the Embozene(TM) Color-Advanced Microspheres. The material handled well, going immediately into suspension and, importantly, staying in suspension. The fact that Embozene(TM) Microspheres are color coded to size is an appealing feature that allows good visibility of the material and clearly creates a higher and important safety profile. CeloNova has apparently carefully engineered these beads to be extremely 'friendly' for the physician to use. I found in these first patients that the product was highly manageable during the procedure. I achieved the procedural goals to devascularize the tumors quickly, using much less material than other products, having far less radiation time for the patient, and requiring less contrast media. These are all important and present features."
Embozene(TM) Microspheres are the first and only microspheres to be color- enhanced with a different color for each size for increased procedural safety, efficiency and visibility. They are also available in a wider range of sizes than any other spherical embolic on the market. They are available in 40, 100, 250, 400, 500, 700, and 900 micron sizes in 1 ml and 2 ml pre-filled syringes and vials.
CeloNova's Embozene(TM) Microspheres consist of a hydrogel core and an exterior shell made from Polyzene(R)-F, CeloNova's proprietary polymer which is known to be anti-inflammatory and bacterial-resistant. Four design features distinguish Embozene(TM) Microspheres from other spherical embolics: biocompatibility, precise calibration, stable suspension, and structural stability. Embozene(TM) Microspheres are precisely calibrated, they retain their shape after passing through a catheter, and they can stay in suspension for an extended time. The unique color enhancement of the microspheres and finely calibrated sizes make selection easy, efficient, and precise for the operator. The result is an embolic microsphere that provides accurate and complete vessel occlusion.
"Dr. Lipman is a recognized leader in embolization therapy and we are extremely pleased that he was the first U.S. physician to implant our newly approved Embozene(TM) Microspheres with such wonderful results," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "From the outset, we took a different approach to developing our Embozene(TM) Microspheres by asking physicians and medical scientists for the qualities and characteristics that the ideal embolic device should have. Then, we engineered in those properties physicians wanted and engineered out those properties that physicians did not want. Embozene(TM) Microspheres are made even better with Polyzene(R)-F, our proprietary polymer. Polyzene(R)-F helps make our leading- edge technology better."
For more information about CeloNova BioSciences, visit www.celonova.com or call 888-388-3888 to reach your local sales representative or e-mail email@example.com.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit www.celonova.com.
Polyzene(R)-F is a synthesized inorganic chemical compound with an extensive array of bioscience and industrial applications that can be applied as a surface coating ranging in thickness from less than 50 nanometers to more than 200 nanometers. The polymer can be applied to or mixed with other substances to allow for a diverse range of applications on a multitude of substrates, including other polymers, metals and ceramics. Polyzene(R)-F can be customized for the desired application and applied in a variety of ways including as a coating, extrusion, weaving, or electro-spinning. The base substrate will be endowed with the properties of the polymer.
Press Contact: Robert J. Murphy
CONTACT: Robert J. Murphy, The Storch-Murphy Group, +1-908-276-0777, for
CeloNova BioSciences, Inc.
Web site: http://www.celonova.com/